| P/E (FY) | 14.7 | Sales (TTM) | €525.7M |
| Earnings (TTM) | €57.4M | ROE | 9.83% |
| Net Margin | 10.91% | ROIC | 14.98% |
| Debt / Equity | 0.00 | TD / EBITDA | — |
| EPS Growth 3Y | 6.76% | Sales Growth 3Y | −0.88% |
Vetoquinol is a veterinary pharmaceutical company that designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats across Europe, the Americas, and the Asia Pacific region. Its product areas include mobility, pain and inflammation, dermatology and hygiene, anti-parasitics, udder health, antibiotics, reproduction, behavior management, internal medicine, and cardio-nephrology. The company is headquartered in Lure, France.
| Market Cap | $958.2M | Trading Days | 4175 |
| 52W High | 91.50 |
| 52W Low | 67.20 |
| % Off High | −20.66% |
| YTD | −11.87% | 1Y | −6.85% |
| 3Y | −18.91% | 5Y | −30.01% |
| 10Y | 105.17% | Since incept. (ann.) | 8.51% |
| Ann. Volatility (1Y) | 26.43% | Ann. Volatility (3Y) | 29.20% |
| Sharpe (1Y) | −0.15 | Sharpe (3Y) | −0.09 |
| Max Drawdown (1Y) | −25.15% | Max Drawdown (3Y) | −40.98% |
| Beta (3Y, vs SPY) | 0.41 |
No same-industry peers in the universe for VETO.PA.
